Dermapharm Holding SE
FSX:DMP.DE
30.8 (EUR) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) EUR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,135.351 | 1,024.776 | 942.912 | 793.829 | 700.879 | 572.424 | 467.117 | 444.478 | 384.843 | 391.34 |
| Cost of Revenue
| 792.49 | 363.943 | 322.218 | 330.348 | 317.159 | 272.66 | 245.644 | 243.448 | 205.042 | 220.312 |
| Gross Profit
| 342.861 | 660.833 | 620.694 | 463.481 | 383.72 | 299.764 | 221.473 | 201.03 | 179.801 | 171.028 |
| Gross Profit Ratio
| 0.302 | 0.645 | 0.658 | 0.584 | 0.547 | 0.524 | 0.474 | 0.452 | 0.467 | 0.437 |
| Reseach & Development Expenses
| 10.628 | 13.178 | 14.174 | 12.662 | 11.207 | 6.957 | 6.64 | 4.821 | 4.621 | 7.34 |
| General & Administrative Expenses
| 20.24 | 16.103 | 13.069 | 14.682 | 12.66 | 9.832 | 6.928 | 3.246 | 3.464 | 3.041 |
| Selling & Marketing Expenses
| 75.043 | 50.645 | 52.813 | 51.927 | 38.967 | 24.784 | 14.786 | 14.83 | 13.695 | 14.951 |
| SG&A
| 131.886 | 66.748 | 65.882 | 66.609 | 51.627 | 34.616 | 21.714 | 18.076 | 17.159 | 17.992 |
| Other Expenses
| 433.148 | 338.858 | 253.595 | 238.94 | 201.143 | 149.327 | 102.304 | 92.036 | 90.38 | 101.475 |
| Operating Expenses
| 142.514 | 418.784 | 333.651 | 318.211 | 263.977 | 190.9 | 130.658 | 114.933 | 112.16 | 126.807 |
| Operating Income
| 200.347 | 243.687 | 298.469 | 136.853 | 119.513 | 107.509 | 92.116 | 86.794 | 60.763 | 43.255 |
| Operating Income Ratio
| 0.176 | 0.238 | 0.317 | 0.172 | 0.171 | 0.188 | 0.197 | 0.195 | 0.158 | 0.111 |
| Total Other Income Expenses Net
| -87.187 | -27.39 | -5.492 | -11.57 | -9.447 | -3.272 | -4.086 | -3.231 | -12.342 | -8.734 |
| Income Before Tax
| 113.16 | 216.297 | 292.977 | 125.283 | 110.066 | 104.237 | 88.03 | 82.866 | 55.299 | 35.487 |
| Income Before Tax Ratio
| 0.1 | 0.211 | 0.311 | 0.158 | 0.157 | 0.182 | 0.188 | 0.186 | 0.144 | 0.091 |
| Income Tax Expense
| 45.463 | 83.68 | 84.073 | 39.357 | 32.254 | 29.011 | 10.286 | 5.871 | 2.92 | 2.244 |
| Net Income
| 62.368 | 134.236 | 209.583 | 85.826 | 77.196 | 75.323 | 77.744 | 16.824 | 12.701 | -0.061 |
| Net Income Ratio
| 0.055 | 0.131 | 0.222 | 0.108 | 0.11 | 0.132 | 0.166 | 0.038 | 0.033 | -0 |
| EPS
| 1.16 | 2.49 | 3.89 | 1.59 | 1.43 | 1.41 | 1.56 | 1.54 | 0.24 | -0.001 |
| EPS Diluted
| 1.16 | 2.49 | 3.89 | 1.59 | 1.43 | 1.41 | 1.56 | 1.43 | 0.24 | -0.001 |
| EBITDA
| 304.934 | 328.549 | 348.259 | 190.604 | 169.568 | 140.42 | 111.654 | 105.577 | 94.59 | 75.14 |
| EBITDA Ratio
| 0.269 | 0.321 | 0.369 | 0.24 | 0.242 | 0.245 | 0.239 | 0.238 | 0.246 | 0.192 |